ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 148 filers reported holding ACCELERON PHARMA INC in Q4 2016. The put-call ratio across all filers is 3.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $34,390,000 | -20.6% | 1,347,553 | +12.6% | 0.01% | -33.3% |
| Q3 2016 | $43,321,000 | +13.0% | 1,197,052 | +6.1% | 0.01% | +12.5% |
| Q2 2016 | $38,332,000 | +35.7% | 1,128,078 | +5.4% | 0.01% | +14.3% |
| Q1 2016 | $28,240,000 | -37.1% | 1,070,110 | +16.2% | 0.01% | -30.0% |
| Q4 2015 | $44,904,000 | +83.8% | 920,917 | -6.2% | 0.01% | +66.7% |
| Q3 2015 | $24,436,000 | -17.9% | 981,351 | +4.3% | 0.01% | -14.3% |
| Q2 2015 | $29,769,000 | -5.2% | 940,872 | +14.1% | 0.01% | 0.0% |
| Q1 2015 | $31,389,000 | +1.8% | 824,732 | +4.2% | 0.01% | -12.5% |
| Q4 2014 | $30,831,000 | +186.9% | 791,349 | +122.7% | 0.01% | +166.7% |
| Q3 2014 | $10,748,000 | -12.7% | 355,415 | -1.9% | 0.00% | 0.0% |
| Q2 2014 | $12,312,000 | +78.4% | 362,428 | +81.1% | 0.00% | +50.0% |
| Q1 2014 | $6,903,000 | -0.4% | 200,099 | +14.4% | 0.00% | 0.0% |
| Q4 2013 | $6,928,000 | – | 174,954 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |